What Every Hospice CFO Should Know About Pharmacy Spend
Pharmacy is one of the three largest cost categories in hospice operations — alongside labor and clinical supplies. Unlike labor, pharmacy spend has structural levers that financial leaders can pull without affecting clinical quality. Unlike supply costs, pharmacy is often governed by a contractual arrangement that may or may not be delivering the financial performance the organization deserves.
For hospice CFOs, the pharmacy benefit arrangement is a balance sheet item that deserves the same scrutiny as any major vendor contract. Most hospice financial leaders, however, inherited their pharmacy arrangement rather than designed it — and many are operating without the benchmarking data to know whether their current PPD is competitive.
This is what financial leadership over pharmacy spend actually looks like.
The Core Financial Metric: PPD
Per-patient-per-day drug cost (PPD) is the primary financial benchmark for hospice pharmacy. It measures total pharmacy spend divided by total patient census days — giving you a normalized cost figure that tracks cleanly regardless of census size or seasonal variation.
Industry benchmarks:
- Average hospice PPD: $8-$12
- Optimized hospice PPD (structured PBM arrangement): $5-$6
- MaxHaven average PPD: $5.44
The gap between $10 PPD and $5.44 PPD is not marginal. Across 100 patients, the annual difference in pharmacy spend is more than $165,000. For a hospice operating at Medicare per diem rates that do not adjust for pharmacy costs, that $165,000 stays in the organization or goes to drug spend — there is no third option.
CFOs who do not have a current PPD figure — or who have one but cannot benchmark it against peer organizations — are flying without instruments on one of their largest cost lines.
Why Pharmacy Contracts Produce Opaque Results
Most pharmacy contracts are structured in ways that make financial analysis difficult. This is not accidental. Traditional pharmacy benefit arrangements — including many retail pharmacy accounts and national PBM contracts — are designed around pricing models that obscure the relationship between what the organization pays and what drugs actually cost.
Spread pricing is the practice of billing the organization more per drug than the PBM pays the dispensing pharmacy, with the PBM retaining the difference. In a spread-pricing arrangement, there is no way to know from standard claims reporting what the actual drug cost was — only what you were billed. The “spread” is proprietary information that the PBM does not disclose.
Retained rebates work similarly. Drug manufacturers pay rebates to PBMs in exchange for formulary positioning. A traditional PBM contract may guarantee the plan a percentage of rebates — while retaining a portion of the total rebate pool without disclosing the full amount. The organization receives a rebate; it simply cannot verify whether it received all of it.
For a hospice CFO preparing quarterly financial reports or board presentations, a pharmacy contract that does not produce auditable, transparent data is a governance risk — not just a cost optimization problem.
What a Transparent PBM Arrangement Looks Like
MaxHaven operates on a no-spread-pricing model. The financial structure is straightforward:
- The organization pays the actual acquisition cost of every drug dispensed
- MaxHaven charges a transparent, fixed administrative fee per claim
- There is no spread between acquisition cost and billing
- All drug discounts flow through to the organization directly
The result is a claims file where every line item is verifiable. Drug cost is drug cost. The administrative fee is the administrative fee. A CFO — or an external auditor — can review the data and confirm that what the organization paid matches what drugs cost, without any ambiguity.
MaxHaven clients have full audit rights. If your finance team or external auditors want to verify pharmacy spend, the data is available and the audit process is defined in the contract.
Budget Forecasting and PPD Trend Analysis
For CFOs building annual operating budgets, pharmacy spend has historically been one of the harder line items to forecast accurately. Patient acuity fluctuates. New high-cost drugs enter the formulary. Census changes create per-unit cost swings.
A structured MaxHaven arrangement changes the forecasting picture in two ways:
PPD benchmarking provides a reference range. Rather than projecting pharmacy spend from last year’s actuals — which may reflect one-time outliers or census anomalies — a MaxHaven client can benchmark against industry PPD data for similar organizations. The forecast becomes grounded in what comparable programs actually spend, not just what you spent last quarter.
Formulary controls limit outlier exposure. High-cost drug claims — specialty medications, off-formulary requests, high-acuity pain management — are the primary source of pharmacy budget variance. MaxHaven’s formulary management process includes prior authorization for high-cost items and formulary exception review, which catches outliers before they compound. For budget purposes, this means fewer surprises.
What to Ask Before Renewing Your Pharmacy Contract
If your pharmacy arrangement is coming up for renewal — or if you have never formally reviewed the financial structure of your current arrangement — these are the questions that matter.
On pricing structure — verify, don’t just ask: Every PBM will tell you it is pass-through, so what matters is not what your vendor calls its pricing but what the numbers actually show. Ask your vendor to provide:
- What the dispensing pharmacy was actually paid on our claims, shown side by side with what we were billed. Any difference between the two is spread pricing — no matter how the arrangement is labeled.
- Actual acquisition cost versus billed cost on our top 20 drugs by spend.
On audit rights:
- Do we have the contractual right to audit actual pharmacy payment records — not just claims data?
- Is there a defined process for remediating findings if a spread is discovered?
On benchmarking:
- What is our current PPD, and how does it rank against peer organizations?
- What formulary changes would move our PPD toward the optimized range?
If you find a spread: Spread pricing is now restricted or prohibited in a growing number of states. If your billed-versus-paid comparison turns up a spread and your state limits the practice, you can raise it with the authority responsible for PBM oversight — usually the state department of insurance, though it varies by state (in Oklahoma, for example, that responsibility sits with the Attorney General’s Office).
If your current vendor cannot answer these questions with documented, contract-backed specificity — the answer is buried in your financial reports somewhere, and it is costing you.
The MaxHaven CFO Conversation
MaxHaven provides a no-cost pharmacy spend analysis for hospice organizations evaluating their current arrangement. We will pull your current claims data, calculate your PPD, benchmark it against industry data for your patient mix, and model what a MaxHaven arrangement would look like in dollar terms.
The analysis takes two weeks from the time we receive your data. The output is a clear financial picture: what you are spending, what you should be spending, and what the path to optimized PPD looks like. No sales pressure. Just the numbers.
For hospice CFOs who want the same financial clarity over pharmacy that they apply to every other major cost category, that conversation is the place to start.
Pharmacy spend is too large to manage without transparency. Let’s look at your numbers.
Request a CFO Pharmacy Spend Analysis → https://maxhavenrx.com | Talk to a MaxHaven Specialist
MaxHaven RX is a hospice-specialized pharmacy benefit manager and part of the PPOK family of pharmacy brands. We serve hospice CFOs, administrators, executive leaders, non-profit programs, hospital-based programs, and new organizations. Our average PPD: less than $6.00
